The Pharmaceutical Journal
Vol 269 No 7222 p634
2 November 2002

This article
Reprint
Photocopy

News summary

Related websites
American College of Rheumatology (www.rheumatology.org)

Combination therapy benefits RA

Interim results from a phase II trial involving 122 patients reveal that, after six months of treatment, 80 per cent of patients taking methotrexate plus rituximab (MabThera) showed a 20 per cent improvement in their rheumatoid arthritis, compared with only a third of those taking standard methotrexate monotherapy (P=0.001). The data were presented at the annual American College of Rheumatology meeting in New Orleans last month.